Hikal Quarterly Results
Hikal quarterly results. In Mar 2026, Hikal (HIKAL) reported revenue ₹524 Cr and net profit ₹14 Cr — revenue -4.9% YoY. For annual financials, live price and key ratios, visit Hikal share price screener.
HIKAL Quarterly Results — Revenue, Profit & EPS Highlights
Hikal latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Hikal market cap to track the company's total market size over time.
- Revenue of ₹524 Cr in Mar 2026 (+27.5% vs Jun 2026, -4.9% vs Mar 2025)
- Net Profit of ₹14 Cr in Mar 2026 (+300.0% vs Jun 2026, -72.0% vs Mar 2025)
- EBITDA of ₹63 Cr in Mar 2026 (+40.0% vs Jun 2026)
- Operating Margin of 11.0% in Mar 2026 (+2.0pp vs Jun 2026)
- Earnings Per Share of ₹1.17 in Mar 2026 (+295.0% vs Jun 2026)
Hikal Quarterly Results — Revenue, EBITDA, Net Profit & EPS
HIKAL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 524 | 411 | 318 | 551 | 372 | 27.5% | -4.9% |
| Net Profit (₹ Cr) | 14 | -7 | -35 | 50 | -22 | - | - |
| EBITDA (₹ Cr) | 63 | 45 | 7 | 122 | 17 | - | - |
| EPS (₹) | 1.17 | -0.60 | -2.83 | 4.07 | -1.82 | - | - |
| Operating Margin (%) | 11.0% | 9.0% | 2.0% | 22.0% | 4.0% | - | - |
HIKAL Share Price Trend — 1-Year Movement Across Quarterly Results
Hikal 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review HIKAL PE ratio trends to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
HIKAL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Hikal latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores